BICX is the hot new treatment for alcohol abuse

About BioCorRx Program Overview BioCorRx (OTCBB: BICX) is an alcohol treatment and rehabilitation company on the leading edge of alcohol addiction treatment. The company has developed a treatment program that is used by various licensed alcohol addiction clinics throughout the United States. The program consists of two components: BioCorRx has the worldwide rights (except in Australia and New Zealand) to a highly effective, proprietary implant formulation of the FDA-approved drug, naltrexone. After being surgically implanted by a medical professional, the naltrexone implant significantly reduces cravings for alcohol for as long as a year in some patients, depending on individual metabolism rates. BioCorRx also owns a life coaching program that is tailored specifically to alcoholics. Once a patient has received the implant, they are encouraged to enter the life coaching program to maximize results. BioCorRx ’s revolutionary alcohol treatment program has an 85% success rate as reported by patients in routine telephone and face to face interviews . The implant is administered as an outpatient procedure, and in most cases, patients do not need to miss more than one day of work. They are then able to enter the private life coaching program without co-workers or family members knowing, unless they so choose.

Technology

Naltrexone is a medication that blocks the effects of drugs known as opioids and was approved by the FDA in 1995 for the treatment of alcohol dependence.

Learn more about the side effects of naltrexone.

Naltrexone blocks the parts of the brain that "feel pleasure” when patients use alcohol. When these areas of the brain are blocked, patients feel significantly less cravings for alcohol and even if alcohol is used, the effects of it will be extremely limited - making sobriety the only option. Once medical intervention has reduced the physical need for alcohol, the program goes on to address the patient's psychological needs. The combination of these treatments has resulted in the highest chance of sobriety.

While other companies use naltrexone in their treatments, the drug is typically administered in oral or injection form, requiring their patients to be responsible for taking the medication or scheduling an appointment.

While some patients do well with the oral formulation, there is a drawback that it must be taken daily and a patient whose craving becomes overwhelming can obtain the euphoria simply by skipping a dose before resuming abuse. Patients who received the program developed by BioCorRx are treated with a slow release dose that can last up to year in many patients (depending on various factors such as metabolism rates), which gives the patients a higher success rate for the treatment of alcoholism.

The outpatient naltrexone implant procedure can take as little as 20 minutes under local anesthetic in some cases. Most patients can return to work or their daily routine in the same day, without the cravings for alcohol.